Revenue: As of FY2025 Q1, the actual value is USD 13.14 M.

EPS: As of FY2025 Q1, the actual value is USD -0.48.

Segment Revenue

• Journey Medical’s net product revenues for the first quarter ended March 31, 2025, were $13.1 million, compared to $13.0 million for the first quarter ended March 31, 2024.

Operational Metrics

• Consolidated research and development expenses totaled $3.9 million for the first quarter ended March 31, 2025, compared to $24.8 million for the first quarter ended March 31, 2024.
• Consolidated selling, general and administrative costs were $25.7 million for the first quarter ended March 31, 2025, compared to $17.9 million for the first quarter ended March 31, 2024.
• Consolidated net loss attributable to common stockholders was - $12.7 million, or - $0.48 per share, for the first quarter ended March 31, 2025, compared to - $17.9 million, or - $1.04 per share for the first quarter ended March 31, 2024.

Cash Flow

• As of March 31, 2025, Fortress’ consolidated cash and cash equivalents totaled $91.3 million, compared to $57.3 million as of December 31, 2024, an increase of $34.0 million during the quarter.

Unique Metrics

• Fortress owns approximately 6.9 million shares of Checkpoint’s common stock and is eligible to receive a 2.5% royalty on future sales of UNLOXCYT.

Outlook / Guidance

• Fortress is focused on key value drivers, including the September 30, 2025 PDUFA action date for CUTX-101, which may result in a Priority Review Voucher for Cyprium Therapeutics upon approval. The commercial launch of Emrosi is underway with initial prescriptions filled at the end of March. Fortress’ robust pipeline positions the company for continued revenue growth, value-driving milestones, and additional monetization opportunities.